Artelo Biosciences Inc
Research Artelo Biosciences Inc (ARTL) on Bullrun: market cap USD 13.65M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerARTL
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 13.65M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 2.43M
- Free cash flow-USD 5.03M
Valuation Snapshot
latest market cap is USD 13.65M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 12.88M | -USD 8.52M | n/a | -37.75 | USD 600.00K | USD 678.00K | -USD 1.27M |
| FY2024 | USD 0 | -USD 9.83M | -USD 8.35M | n/a | -54.89 | USD 2.34M | USD 104.00K | USD 2.86M |
| FY2023 | USD 0 | -USD 9.29M | -USD 8.21M | n/a | -18.8 | USD 2.82M | USD 23.00K | USD 11.75M |
| FY2022 | USD 0 | -USD 10.08M | -USD 8.01M | n/a | -64.08 | USD 6.89M | USD 63.00K | USD 19.40M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 13.65M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 2.46M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 3.61M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 4.47M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 8.25M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 21.96M | n/a | n/a | n/a |
About Artelo Biosciences Inc
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Artelo Biosciences Inc's market cap?
Artelo Biosciences Inc's market capitalization is USD 13.65M.
What does Artelo Biosciences Inc do?
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications.